Related Experiment Videos

Effect of nicotinamide on newly diagnosed type 1 diabetic children

Madeeha Kamal1, Abdul-Jabbar Al Abbasy, Ahood Al Muslemani

  • 1Department of Pediatrics, Salmaniya Medical Complex, Manama, Bahrain.

Acta Pharmacologica Sinica
|May 26, 2006
PubMed

Insights

Low-dose nicotinamide (NA) therapy in children with new-onset type 1 diabetes reduced insulin needs and extended the remission (honeymoon) period. This suggests NA may help manage pediatric type 1 diabetes.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Pediatric Diabetes Management

Background:

  • Type 1 diabetes (T1D) is an autoimmune disease characterized by pancreatic beta-cell destruction.
  • The 'honeymoon period' in T1D is a temporary phase of reduced insulin needs post-diagnosis.
  • Maintaining beta-cell function is crucial for long-term T1D management.

Purpose of the Study:

  • To investigate the efficacy of early low-dose nicotinamide (NA) therapy in pediatric patients with newly diagnosed type 1 diabetes.
  • To determine if NA treatment can prolong the remission period and decrease insulin requirements.
  • To assess the impact of NA on glycemic control in children with T1D.

Main Methods:

  • A cohort of 66 pediatric patients with newly diagnosed T1D received nicotinamide (1-2 mg/kg/day) within 24 hours of diagnosis.
  • Patients were followed for 24 months, with insulin dosage per kg bodyweight recorded at 3-month intervals.
  • Results were compared to a control group (n=37) diagnosed between 1995-1997 who did not receive NA.

Main Results:

  • No significant differences in baseline characteristics (age, weight, insulin dose, glucose levels) were observed between the NA and control groups.
  • The NA group consistently demonstrated lower insulin requirements compared to the control group at all 3-month intervals up to 2 years post-diagnosis.
  • This indicates a potential benefit of NA in reducing exogenous insulin needs.

Conclusions:

  • Early administration of low-dose oral nicotinamide may be beneficial in managing pediatric type 1 diabetes.
  • NA therapy appears to reduce insulin requirements and potentially prolong the honeymoon period in children with newly diagnosed T1D.
  • Further research is warranted to confirm these findings and explore optimal NA dosing strategies.
Abstract

Related Concept Videos

Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...